Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Skye Bioscience Inc SKYE

Skye Bioscience, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system. The Company's clinical assets focus on the modulation of cannabinoid receptor 1 (CB1) to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. Its Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion (SBI-100 OE), a CB1 agonist (activator), being developed for the treatment of glaucoma and ocular hypertension. The Company's Phase 2 study in obesity is designed to evaluate nimacimab's weight loss potential either as a single agent or in combination with a glucagon-like peptide-1 (GLP-1) agonist like semaglutide.


NDAQ:SKYE - Post by User

Post by Stockqueen77on Aug 05, 2021 4:15pm
456 Views
Post# 33658616

The arrest of AVTAR DHILLON

The arrest of AVTAR DHILLON
Cannabis and Biotech Board Chair Arrested for Securities Fraud BY BRE BRADHAM Aug. 5, 2021, 8:47 AM Listen A cannabis and biotechnology entrepreneur was arrested and charged with securities fraud over his secret sale of shares in two companies in which he served as board chairman. Avtar S. Dhillon, 60, executive chairman of medical marijuana firm Emerald Health Therapeutics Inc., was arrested Wednesday on charges brought by federal prosecutors in Boston, who said he made more than $2 million from the scheme. Dhillon, a Canadian national living in California, will make his initial appearance in federal court in Boston at a later date. A lawyer for Dhillon couldnt immediately be identified. Vancouver-based Emerald Health declined to comment on Dhillons arrest. According to the government, Dhillon concealed from regulators his ownership of millions of shares in Arch Therapeutics Inc. and OncoSec Medical Inc., two microcap biotech firms. He was board chairman at Arch from 2013 to 2018 and OncoSec from 2011 to 2020. Dhillon and a co-conspirator made false and misleading representations in order to deposit and then sell the shares in the open market to unsuspecting investors, the government said. From 2005 to 2009, Dhillon was chief executive officer of Inovio Pharmaceuticals Inc.
<< Previous
Bullboard Posts
Next >>